Long-term Use and Safety of JAK Inhibitors and Evaluating Efficacy Outcomes in Atopic Dermatitis : Episode 1

Video

June 5, 2023

Standard of Care in AD

Author(s):

Christopher G. Bunick, MD, PhD

Christopher G. Bunick, MD, PhD, discusses what can be done to improve the standard of care for atopic dermatitis (AD).

EP: 1.Standard of Care in AD

EP: 2.Clinical Outcomes in AD Clinical Trials

EP: 3.EASI Scores in AD Treatment

EP: 4.NRS in AD Treatment

EP: 5.AD: Efficacy Outcomes

EP: 6.RAD 2023 AD Trial: Meta-Analysis Data

EP: 7.AD Clinical Approach: Switching Therapies

EP: 8.Topical and Systemic Treatments for AD

EP: 9.Pathophysiology of AD Treatments

EP: 10.Treatment Selection in AD

EP: 11.JAK Inhibitor Safety

EP: 12.AD Treatment: Upadacitinib

EP: 13.Switching Therapies in AD

Related Videos

Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD

ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis

Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis

Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa

Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD

Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD

2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD

2 Helpful Clinical Tips for Dermatologists, with Eingun James Song, MD

What Are Some Other Methods To Manage Skin Cancer Outside of Biopsies?

Related Content

Related Content

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.